BerGenBio to Participate in Carnegie Nordic Healthcare Seminar
BERGEN, Norway, March 4, 2024 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, announced today that the Company will present at Carnegie’s 27th Annual Nordic Healthcare Seminar to be held on March 5th - 6th, 2024 in Stockholm, Sweden. The presentation will be live streamed by Carnegie on March 6th from 9:40 am CET. The presentation will also be made available on the Company website in the Investor/presentations section following the presentation. www.bergenbio.com/